Bio-Outsourcing

52 Results

CDMO Process Development Template

MilliporeSigma - Gene Therapy | 26-Oct-2020 | Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...

Infographic - road map to commercialization

MilliporeSigma - Gene Therapy | 19-Oct-2020 | Infographic

With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization...

Process Development for Viral Vector Manufacturing

MilliporeSigma - Gene Therapy | 15-Oct-2020 | Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...

Your Gene Therapy Partner From Discovery To Commercialization

MilliporeSigma - Gene Therapy | 12-Oct-2020 | Product Presentation

The MilliporeSigma organization is dedicated to supporting your cell and gene therapy from early phase through product release. Not only does our BioReliance®...

Robust, load-independent viral clearance in monoclonal antibody purification with Natrix® Q chromatography membrane

Viral Safety for mAb: Prevent, Detect, Remove | 12-Oct-2020 | Application Note

Anion exchange chromatography is an important step for viral clearance of monoclonal antibodies. Natrix® Q chromatography membrane improves cost-efficiency....

Updated US FDA Guidance For The Gene Therapy Industry: Key Changes And Areas Of Increased Focus.

MilliporeSigma - Gene Therapy | 01-Oct-2020 | Application Note

In January 2020, the United States Food and Drug Administration (FDA) released several new or updated guidance documents pertaining to human gene therapy...

Accelerating Cell Line and Process Development

Take the Right Path Upstream with MilliporeSigma | 01-Oct-2020 | Technical / White Paper

Development of a high-producing cell line supported by a robust upstream process are critical early steps in the production of monoclonal antibodies (mAbs)....

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Reducing The Risk During Cell And Gene Therapy Development And Manufacturing

MilliporeSigma - Gene Therapy | 05-Aug-2020 | Technical / White Paper

While new modalities are generating significant excitement among patients and caregivers, cell and gene therapy manufacturers are experiencing growing...

Suppliers

Baxter BioPharma Solutions

Marken

Product Innovations

Survey Report: State of the global biomanufacturing and bioprocessing industry 2017

In September 2017, BioPharma-Reporter.com conducted its second annual ‘state of the industry’ survey on its user base of biopharmaceutical industry professionals....

Survey Report: State of the Biopharmaceutical Industry 2016

In May 2016, BioPharma-Reporter conducted its inaugural ‘state of the industry’ survey. The key objective of the poll was to gauge views about the current...